⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3224780 | 1.00 | — | — | |
| SCHEMBL3453511 | 0.84 | — | — | |
| SCHEMBL21618349 | 0.84 | — | — | |
| SCHEMBL23539089 | 0.83 | — | — | |
| SCHEMBL18202988 | 0.83 | — | — | |
| SCHEMBL20115811 | 0.83 | — | — | |
| SCHEMBL4034941 | 0.80 | PKM (0.35) | — | |
| SCHEMBL1732829 | 0.78 | — | — | |
| SCHEMBL14932913 | 0.78 | — | — | |
| SCHEMBL20024141 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20260042759-A1 | INHIBITOR CONTAINING BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) | 2026-02-12 | — | — | US | disclosed |
| US-20260027221-A1 | Targeted Pyrrolobenzodiazapine Conjugates | BEONE MEDICINES I GMBH (CH) | 2026-01-29 | — | — | US | disclosed |
| US-12466823-B2 | Inhibitor containing bicyclic derivative, preparation method therefor and use thereof | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2025-11-11 | — | — | US | disclosed |
| EP-4251610-B1 | COSMETIC SUCCINIMIDE COMPOUNDS | TARA BRANDS EUROPE S L U (ES) | 2025-05-28 | — | — | EP | disclosed |
| CN-119954801-A | TAU protein targeting compounds and related methods of use | 阿尔维纳斯运营股份有限公司 | 2025-05-09 | — | — | CN | disclosed |
| EP-3971187-B1 | INHIBITOR CONTAINING BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) | 2025-05-07 | — | — | EP | disclosed |
| CN-114867727-B | TAU protein targeting compounds and related methods of use | 阿尔维纳斯运营股份有限公司 | 2025-02-21 | — | — | CN | disclosed |
| US-20250017836-A1 | COSMETIC COMPOUNDS | TARA BRANDS EUROPE S.L.U. (ES) | 2025-01-16 | — | — | US | disclosed |
| CN-118891249-A | Cosmetic compound | 塔拉品牌欧洲有限公司 | 2024-11-01 | — | — | CN | disclosed |
| US-9796686-B2 | Antibacterial quinazoline-4(3H)-one derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-10-24 | — | — | US | disclosed |
| US-20170204109-A1 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-07-20 | — | — | US | disclosed |
| US-20170204109-A1 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-07-20 | — | — | US | disclosed |
| US-20170204109-A1 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-07-20 | — | — | US | disclosed |
| US-20170107223-A1 | 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-04-20 | — | — | US | disclosed |
| US-9624206-B2 | Antibacterial 1H-indazole and 1H-indole derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2017-04-18 | — | — | US | disclosed |
| US-20170081292-A1 | ANTIBACTERIAL QUINAZOLINE-4(3H)-ONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-03-23 | — | — | US | disclosed |
| US-20170029411-A1 | ANTIBACTERIAL 1H-INDAZOLE AND 1H-INDOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2017-02-02 | — | — | US | disclosed |
| US-20160221959-A1 | ANTIBACTERIAL 2H-INDAZOLE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2016-08-04 | — | — | US | disclosed |
| WO-2016011930-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-01-28 | — | — | WO | disclosed |